Organovo (ONVO) Stock Analysis

What Organovo does

Organovo Holdings, Inc. is a biotechnology firm that specializes in engineering sophisticated 3D tissues designed to accurately mimic critical facets of human diseases. Central to its operations is a comprehensive 3D human tissue platform, which features the company's proprietary NovoGen Bioprinters. These automated devices are crucial for fabricating complex, living 3D tissues from mammalian cells. The platform also includes supporting technologies necessary for creating specialized "bio-inks" and for the bioprinting of multi-cellular tissues with intricate structures. Organovo supplies specific products, such as ExVive human liver tissue and ExVive human kidney tissue, which are employed for predictive preclinical evaluation of investigational drug compounds. The company was founded in 2007 and maintains its corporate headquarters in Solana Beach, California.

Key metrics

ETFs linked to ONVO

Broad-market and Healthcare sector ETFs an investor holding Organovo is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ONVO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Organovo?

Organovo trades under the ticker ONVO on NASDAQ.

Which exchange is ONVO listed on?

ONVO is listed on NASDAQ.

What sector does Organovo operate in?

Organovo is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ONVO in a portfolio?

PortView shows ONVO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.